Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (32)

2024

  1. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

  2. Thrombus composition and its implication in ischemic stroke assessment and revascularization treatments

    Neurologia

2017

  1. Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease

    Journal of Vascular Surgery, Vol. 66, Núm. 5, pp. 1527-1533.e1

2015

  1. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

  2. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease

    Journal of Vascular Surgery, Vol. 61, Núm. 2, pp. 428-435

  3. Targeting γ-secretases protect against angiotensin II-induced cardiac hypertrophy

    Journal of Hypertension

2008

  1. Asociación de marcadores inflamatorios y aterosclerosis subclínica en relación con la edad en sujetos sin enfermedad cardiovascular

    Medicina Clinica, Vol. 131, Núm. 10, pp. 361-365

  2. Association between matrix metalloproteinase-10 concentration and smoking in individuals without cardiovascular disease

    Revista Espanola de Cardiologia, Vol. 61, Núm. 12, pp. 1267-1273

2007

  1. Aterosclerosis en las enfermedades inflamatorias

    Medicina Clinica, Vol. 128, Núm. 19, pp. 749-756

  2. Metaloproteasa-10 (estromelisina-2): Un nuevo marcador de aterosclerosis subclínica

    Clinica e Investigacion en Arteriosclerosis, Vol. 19, Núm. 3, pp. 122-128

2006

  1. Ciclooxigenasa 2: ¿Una nueva diana terapéutica en la aterosclerosis?

    Medicina Clinica, Vol. 126, Núm. 20, pp. 782-786

  2. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors

    Clinica Chimica Acta, Vol. 368, Núm. 1-2, pp. 138-143

2005

  1. Fibrinógeno. Vieja proteína hemostática con nueva función: Marcador no invasivo de aterosclerosis subclínica

    Medicina Clinica, Vol. 124, Núm. 20, pp. 790-794

  2. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects

    Journal of Thrombosis and Haemostasis, Vol. 3, Núm. 4, pp. 662-664

  3. Monocyte cyclooxygenase-2 overactivity: A new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

    European Heart Journal, Vol. 26, Núm. 2, pp. 153-158

  4. Trombosis arterial y polimorfismos genéticos: Demasiados actores, escenario complejo

    Medicina Clinica, Vol. 124, Núm. 2, pp. 69-74

2004

  1. Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease

    Haematologica, Vol. 89, Núm. 10, pp. 1226-1231

2003

  1. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed

    Atherosclerosis, Vol. 170, Núm. 2, pp. 269-276

  2. Estabilización de la placa de ateroma: Un nuevo concepto basado en la biología dinámica de la aterosclerosis

    Medicina Clinica, Vol. 121, Núm. 15, pp. 583-587

  3. Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects

    Cerebrovascular Diseases, Vol. 16, Núm. 4, pp. 356-362